Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 2-((4-tert-butylcyclohexyl)methyl)-3-hydroxy-1,4-naphthoquinone
2. Bw 720c
3. Bw-720c
1. 88426-33-9
2. Butalex
3. Bw-720c
4. 3-[(4-tert-butylcyclohexyl)methyl]-4-hydroxynaphthalene-1,2-dione
5. Bw 720c
6. 2-((4-tert-butylcyclohexyl)methyl)-3-hydroxy-1,4-naphthoquinone
7. 2-[[4-(1,1-dimethylethyl)cyclohexyl]methyl]-3-hydroxy-1,4-naphthalenedione
8. Chembl3182074
9. 0354rt7lg4
10. Mmv689480
11. 2-((4-(1,1-dimethylethyl)cyclohexyl)methyl)-3-hydroxy-1,4-naphthalenedione
12. Buparvaquonum [latin]
13. Buparvacuona
14. Buparvacuona [spanish]
15. Buparvaquonum
16. 2-((4-(tert-butyl)cyclohexyl)methyl)-3-hydroxynaphthalene-1,4-dione
17. 1,4-naphthalenedione, 2-((4-(1,1-dimethylethyl)cyclohexyl)methyl)-3-hydroxy-
18. Buparvaquone [inn:ban]
19. Brn 5566006
20. Unii-0354rt7lg4
21. 2-[(4-tert-butylcyclohexyl)methyl]-3-hydroxynaphthalene-1,4-dione
22. 1,4-naphthalenedione, 2-[[4-(1,1-dimethylethyl)cyclohexyl]methyl]-3-hydroxy-
23. 2-((4-tert-butylcyclohexyl)methyl)-3-hydroxy-1,4-naphthochinon
24. Buparvaquone [mi]
25. Buparvaquone [inn]
26. (rs,rs,rs,rs)-2-((4-tert-butylcyclohexyl)methyl)-3-hydroxy-1,4-naphthoquinone
27. Dsstox_cid_31638
28. Dsstox_rid_97522
29. Dsstox_gsid_57849
30. Schembl22978
31. Buparvaquone [mart.]
32. Chembl292009
33. Schembl9598809
34. Zinc1073
35. Dtxsid4057849
36. Schembl11030015
37. Schembl21863689
38. Buparvaquone, >=98% (hplc)
39. Ex-a977
40. Bcp09338
41. Tox21_113753
42. Bdbm50504365
43. Mfcd01712789
44. S4971
45. Akos015899876
46. Zinc100233123
47. Zinc100871160
48. Zinc169287877
49. Zinc584567000
50. Ccg-267769
51. Cs-3254
52. Ncgc00253624-01
53. As-12853
54. Butalex;bw 720c;bw-720c;bw720c
55. Hy-17581
56. Cas-88426-33-9
57. Ft-0663898
58. F17374
59. Buparvaquone, Vetranal(tm), Analytical Standard
60. 426b339
61. Sr-05000022562
62. Q-200767
63. Q4998022
64. Sr-05000022562-1
65. 2-[[4alpha-(1,1-dimethylethyl)cyclohexan-1alpha-yl]methyl]-3-hydroxy-1,4-naphthalenedione
66. 2-hydroxy-3-[[(1alpha)-4beta-tert-butylcyclohexyl]methyl]-1,4-naphthoquinone
| Molecular Weight | 326.4 g/mol |
|---|---|
| Molecular Formula | C21H26O3 |
| XLogP3 | 5.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 326.18819469 g/mol |
| Monoisotopic Mass | 326.18819469 g/mol |
| Topological Polar Surface Area | 54.4 Ų |
| Heavy Atom Count | 24 |
| Formal Charge | 0 |
| Complexity | 544 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antiprotozoal Agents
Substances that are destructive to protozoans. (See all compounds classified as Antiprotozoal Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Market Place
ABOUT THIS PAGE
83
PharmaCompass offers a list of Buparvaquone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Buparvaquone manufacturer or Buparvaquone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Buparvaquone manufacturer or Buparvaquone supplier.
PharmaCompass also assists you with knowing the Buparvaquone API Price utilized in the formulation of products. Buparvaquone API Price is not always fixed or binding as the Buparvaquone Price is obtained through a variety of data sources. The Buparvaquone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 0354RT7LG4 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 0354RT7LG4, including repackagers and relabelers. The FDA regulates 0354RT7LG4 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 0354RT7LG4 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 0354RT7LG4 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 0354RT7LG4 supplier is an individual or a company that provides 0354RT7LG4 active pharmaceutical ingredient (API) or 0354RT7LG4 finished formulations upon request. The 0354RT7LG4 suppliers may include 0354RT7LG4 API manufacturers, exporters, distributors and traders.
click here to find a list of 0354RT7LG4 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 0354RT7LG4 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 0354RT7LG4 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 0354RT7LG4 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 0354RT7LG4 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 0354RT7LG4 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 0354RT7LG4 suppliers with NDC on PharmaCompass.
0354RT7LG4 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 0354RT7LG4 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 0354RT7LG4 GMP manufacturer or 0354RT7LG4 GMP API supplier for your needs.
A 0354RT7LG4 CoA (Certificate of Analysis) is a formal document that attests to 0354RT7LG4's compliance with 0354RT7LG4 specifications and serves as a tool for batch-level quality control.
0354RT7LG4 CoA mostly includes findings from lab analyses of a specific batch. For each 0354RT7LG4 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
0354RT7LG4 may be tested according to a variety of international standards, such as European Pharmacopoeia (0354RT7LG4 EP), 0354RT7LG4 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (0354RT7LG4 USP).
